Forbes March 2, 2020
M&A is an omnipresent reality in the biopharma industry, from Big Pharma mega-mergers to smaller acquisitions of emerging startups.
We’ve recently witnessed several large M&A transactions get closed or announced, including BMS-Celgene, Takeda-Shire, and AbbVie-Allergan; according to BMO Capital Markets data, there was nearly $260B in M&A deal activity in 2019. Over the past eight years, we’ve seen over $1 trillion in M&A deal values in aggregate.
For R&D-stage M&A events, more relevant to the loss-making biotech universe, we saw $45B in 2019, similar to the boom years of 2015 and 2018. This year is off to a good start with Gilead’s $4.9B acquisition of Forty Seven Inc, among others.
In short, we’ve seen a huge amount of overall deal...
Today's Sponsors
Today's Sponsor